Intrinsic Therapeutics

Executive Summary

Intrinsic Therapeutics is a privately held medical device company headquartered in Woburn, Massachusetts, focused on advancing spine surgery outcomes. Its flagship product, Barricaid, is a bone-anchored annular closure device that received FDA approval in 2019 for use in lumbar discectomy procedures. The device is designed to seal large annular defects following disc removal, reducing the risk of symptomatic reherniation and subsequent reoperation. Clinical evidence, including a randomized controlled trial and long-term follow-up studies, supports a 65% reduction in reherniation and a 51% reduction in reoperation at 5 years compared to discectomy alone. Despite clinical validation, commercial adoption has been gradual, influenced by surgeon training requirements, reimbursement dynamics, and competitive offerings.

Upcoming Catalysts (preview)

• Q3 2026Publication of 5-year follow-up data from the pivotal trial90% success
• Q4 2026Expansion of CMS coverage or positive national coverage determination60% success
• TBDStrategic acquisition by a larger spine device company40% success